GLOBAL-SAVINGS-GROUP
Global Savings Group (GSG) and Pepper.com (Pepper) have signed a deal to join forces, combining the world’s largest shopping community with Europe’s leading shopping recommendation and rewards company. The transaction marks the biggest deal in the industry in 2022 and creates a European Champion with a global footprint. Together, GSG and Pepper will form a multinational tech company empowering shoppers in more than 20 markets to make more confident shopping decisions. GSG and Pepper will jointly operate the world’s largest shopping community, recommendation and rewards platform connecting brands and retailers with consumers across more than 2bn purchase journeys annually.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130006042/en/
Fabian Spielberger (CEO and Founder Pepper.com) and Gerhard Trautmann (CEO and Co-founder Global Savings Group) are about to join forces. (Photo: Business Wire)
“We are incredibly excited about this industry-disrupting deal that reinforces our leading position in Europe. Together with Pepper, we will significantly enhance our ability to empower consumers and play an even more meaningful role in their daily lives which will open a wide field of development opportunities to shape the future of our industry together. Jointly, we will create a unique, impactful and even more comprehensive portfolio of shopping solutions with huge benefits for consumers, brands, retailers and publishers alike at a scale that's just not possible anywhere else. Together, we will increase our transformative impact and boost GSG’s growth”, states Dr. Gerhard Trautmann, CEO of GSG.
“Our primary focus has always been to offer the best and broadest of money saving solutions to our communities. Our collaboration with GSG will speed up this process significantly as it empowers us to branch out more. Combined, we have more than 20 years of experience in helping people to make smarter decisions and together we will provide even better and more rewarding shopping experiences. Our loyal customers and many more to come will benefit from our combined contents and technologies”, comments Fabian Spielberger, CEO of Pepper.
GSG and Pepper are both market leaders in their fields and have expanded their solutions and services through strategic acquisitions and organic growth. After the 2018 takeover of the UK loyalty specialist Pouch, GSG acquired iGraal and Shoop, the leading French and German cashback brands in 2020 and 2021 respectively, and just recently the US-based consumer brand and domain Coupons.com. Pepper has always shared GSG’s ambition to consolidate the fast-growing market in the sector and has expanded internationally since 2014. Today, Pepper operates market-leading social commerce platforms such as Dealabs, hotukdeals and mydealz. Together, GSG and Pepper will continue to develop and leverage technology to build the leading platform of shopping solutions and services to constantly drive future growth in current and new markets and verticals.
About GSG
GSG is Europe’s largest shopping rewards company with an international footprint across more than 20 markets. The company’s goal is to empower consumers to get more out of life by providing them access to best savings, cashback, deals, product inspiration, reviews and other digital shopping services. Founded in 2012 and headquartered in Munich, GSG employs more than 700 employees in 12 offices across the globe.
About Pepper
Pepper.com is the world's largest shopping community. From its headquarter in Berlin and offices in Guadalajara, London, Lyon and Winnipeg, the Pepper Media Holding operates market-leading social commerce platforms such as Dealabs, hotukdeals and mydealz.de which are used by 25 million consumers per month and influences 12,000 purchase decisions per minute. The company was founded in 2014 by Fabian Spielberger and Paul Nikkel.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130006042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom